sorafenib tosylate · Bayer Hlthcare · NDA 021923
Nexavar
Earliest generic entry, as listed
10 Sep 2028
Blocked by patent: US 9737488, US 9737488, US 9737488.
Listed patents · 4 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 9737488 | product, use U-2107 | 10 Sep 2028 |
| US 9737488 | product, use U-1480 | 10 Sep 2028 |
| US 9737488 | product, use U-1696 | 10 Sep 2028 |
| US 8877933 | substance, product, use U-1624 | 24 Dec 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 021923 · 001 · RLD | tablet, oral | EQ 200MG BASE | 10 Sep 2028 |